prostate cancer
Conditions
Interventions
External beam MR-guided (MR-linac) radiotherapy to the prostate and seminal
vesicles of 5x7Gy (once weekly) with an isotoxic integrated focal boost up to
50Gy to the intraprostatic tumor as visible
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Men aged 18 years or older with histogically proven prostate carcinoma Imaging stage T3b (as defined on mpMRI) N0M0 Intraprostatic lesion visible on MRI Capable of giving informed consent Participation in the MOMENTUM dataregistry
Exclusion criteria
Exclusion criteria: History of radiotherapy to the pelvis or transurethral resection of the prostate (TURP) Contraindications for MRI according to the guidelines of the Department of Radiology, inability to lay on a treatment table for 45-60 minutes or severe claustrophobia Absence of pretreatment PSMA PET CT WHO performance score > 2 International Prostate Symptom Score >= 15 PSA > 30 Prostate volume >100cc
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is acute gastrointestinal and genitourinary toxicity, scored by the Common Terminology Criteria Adverse Events version 5.0. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are late gastrointestinal and genitourinary toxicity, quality of life and biochemical disease free survival defined by the Phoenix consensus definition | — |
Countries
Netherlands
Outcome results
None listed